If you are not happy with the results below please do another search
Vaccines for kids between the ages of 5 and 11 will likely be available in the first half of November, top U.S. infectious disease expert Anthony Fauci said on Oct. 24, predicting a timetable that could see many kids getting fully vaccinated before the end of 2021.
Investigators at Washington University School of Medicine in St. Louis identified a compound that can help sensory neurons in the central nervous system to heal.
Lexington, Mass.-based Agenus withdrew the company’s Biologics License Application (BLA) for the PD-1 inhibitor balstilimab from the U.S. Food and Drug Administration.
The UK Health Security Agency designated a Delta coronavirus subvariant called AY.4.2 as a “Variant Under Investigation,” saying there was some evidence that it could be more transmissible than Delta.
The U.S. Food and Drug Administration placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.
The Centers for Disease Control and Prevention gave the go-ahead for the use of Moderna’s and Janssen’s Covid-19 vaccines as booster shots six months and two months, respectively, after their initial series as well as the approval of mixing and matching vaccines.
Americans can choose a Covid-19 booster shot that is different from their original inoculation but the recommendation is to stick with the vaccine they got first if available, White House chief medical adviser Dr. Anthony Fauci said on Oct. 22.
The Pfizer/BioNTech Covid-19 vaccine showed 90.7 percent efficacy against the coronavirus in a clinical trial of children 5 to 11 years old, the U.S. drugmaker said on Oct. 22.
This Whitepaper discusses the different approaches to real-time qPCR, outlines considerations to help quickly compare previously optimized qPCR assays with a new qPCR Master Mix, offers guidance for optimizing your real-time qPCR assay and provides a tool for comparing qPCR reagent formulations.
Pfizer, Moderna, and AstraZeneca have been running “dress rehearsals” by adapting their current formulations of Covid-19 vaccines to match present known SARS-CoV-2 variants.